Navigation Links
Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Review's Prestigious TR35 List of Top Young Innovators
Date:8/19/2007

Amyris Co-founder Recognized for Role in Engineering Microbes to Produce

Lower Cost Anti-malarials and High-performing Renewable Biofuels;

TR35 2007 Recipients to be Honored at Technology Review's Emerging

Technologies Conference at MIT

EMERYVILLE, Calif., Aug. 15 /PRNewswire/ -- Amyris Biotechnologies is pleased to announce that Neil Renninger, Ph.D., co-founder and senior vice president of development, has been recognized by Technology Review magazine as one of the world's top innovators under the age of 35. Renninger is being recognized for his contributions to the development of a technology platform for engineering metabolic pathways in microbes to make high-value compounds that help address major global health and energy challenges.

This technology was initially applied to reduce the production cost of artemisinin-based anti-malarial drugs. The research and development team co-led by Renninger applied Amyris' technology platform to develop a microbially-derived artemisinin precursor which is expected to reduce the cost of artemisinin to a fraction of its current cost. In the next application of this technology, Renninger and his team identified high-performing hydrocarbon-based transportation biofuels that can be made using similarly engineered microbes. The resulting fuels will be environmentally friendly, cost-effective, and compatible with current engines and distribution infrastructure.

Selected from hundreds of nominees by a panel of expert judges and the editorial staff of Technology Review, the TR35 is an elite group of accomplished young innovators recognized as having the potential to profoundly impact the world, based on their innovation in their respective areas.

"Neil's work will change the lives of generations to come, both in the fight against malaria and in creating sustainable energy alternatives in biofuels," said John Doerr of Kleiner Perkins Caufield & Byers and member of Amyris' Board of Directors. "This is huge! Neil and his colleagues at Amyris are developing a breakthrough technology and are deeply committed to making a difference."

"This tremendous honor is really a testament to the dedicated, talented and driven team that we've assembled," said Dr. Renninger. "I can't think of a better environment to be working in than here at Amyris as we pursue our technology's full potential in areas like sustainable energy."

Renninger brings to Amyris a cross disciplinary understanding of both the micro-world of strain engineering and the macro-world of chemical engineering. He received a doctorate in Chemical Engineering from the University of California, Berkeley focusing on the metabolic engineering of bacterial cells for chemical transformations. Renninger received his undergraduate training in Chemical Engineering from the Massachusetts Institute of Technology, while simultaneously receiving an M.S. in Environmental Engineering.

"The TR35 honors young innovators for accomplishments that are poised to have a dramatic impact on the world as we know it," said Jason Pontin, editor in chief and publisher of Technology Review magazine. "We celebrate their success and look forward to their continued advancement of technology in their respective fields."

Renninger and the other TR35 winners for 2007 will be featured in the September issue of Technology Review magazine and honored at the Emerging Technologies Conference to be held at MIT September 25-27, 2007.

Additional information about past and present TR35 winners and judges is available at http://www.technologyreview.com/tr35/.

For more information about Technology Review's 2007 Emerging Technologies Conference, please visit: http://www.technologyreview.com/events/tretc/index.aspx.

About Amyris Biotechnologies

Amyris Biotechnologies (http://www.amyrisbiotech.com) is applying its proprietary, breakthrough technology to address major global health and energy challenges. Amyris' advanced technology is used to produce high-value compounds to enable the production of lower cost artemisinin-based anti-malarial drugs and a slate of renewable hydrocarbon biofuels which are expected to be cost-effective and compatible with existing engines and distribution infrastructure. Based in Emeryville, CA, Amyris is a privately-held venture backed company whose investors include Khosla Ventures, Kleiner Perkins Caufield & Byers, and TPG Ventures.

About Technology Review, Inc.

Technology Review, Inc., an independent media company owned by MIT, is the authority on the future of technology, identifying emerging technologies and analyzing their impact for leaders. Technology Review's media properties include Technology Review magazine, the oldest technology magazine in the world (founded in 1899); the daily news website TechnologyReview.com; and events such as the annual Emerging Technologies Conference at MIT.


'/>"/>
SOURCE Amyris Biotechnologies

Copyright©2007 PR Newswire.

Related biology technology :

1. Leadership insights from co-founder of Yesmail
2. John Bergman, co-founder of Guild Software
3. Third Wave co-founder shoots for small target in latest project
4. Bruce Maas named CIO at UW-Milwaukee
5. Three finalists named for UW-Madison CIO
6. Eight lawmakers named to Speakers IT task force
7. Hospital named for Madame Curie installs TomoTherapy system
8. Two UW-Madison professors named to National LambdaRail Networking Research Council
9. UW researcher named top innovator
10. Alzheimers drug firm and more winners named in Wisconsin business-plan contest
11. Inacom named Microsofts favorite learning solutions partner of the year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" ... clinical data from its phase 1/2 tendon repair study investigating ... (RCT-01) as a treatment for Achilles tendinosis. ... The clinical trial ... 6 months and showed no serious adverse events related to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... fight against cancer, autoimmune disease and more through a single-cell precision engineering platform, ... proteomics analysis platform developed in the laboratory of Dr. James Heath at ...
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... ... March 27, 2017 , ... A research team ... vascular grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. ... of treating coronary artery disease (CAD). Lam is an assistant professor at the ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
Breaking Biology News(10 mins):